- Molecular NameSimvastatin
- SynonymSimvastatin [Usan:Ban:Inn]; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]
- Weight418.574
- Drugbank_IDDB00641
- ACS_NO79902-63-9
- Show 2D model
- LogP (experiment)4.68
- LogP (predicted, AB/LogP v2.0)4.69
- pka4.3
- LogD (pH=7, predicted)4.69
- Solubility (experiment)0.03 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-4.76
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors1
- No.of HBond Acceptors5
- No.of Rotatable Bonds7
- TPSA72.83
- StatusFDA approved
- AdministrationN/A
- PharmacologyA hypolipidemic drug belonging to the class of pharmaceuticals called "statins". It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus.
- Absorption_valueN/A
- Absorption (description)Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues.
- Caco_2N/A
- Bioavailability3.0
- Protein binding94.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic, simvastatin is a substrate for CYP3A4.
- Half life2~3 h
- ExcretionRenal 13%, faecal 60%
- Urinary ExcretionNegligible
- Clerance7.6 ml/min/kg
- ToxicityAbdominal pain, Asthenia, Constipation, Diarrhea, Dyspepsia, Flatulence, Nausea, Headache, Upper respiratory infection, Myalgia, Eczema, Pruritus, Rash, Cataract.
- LD50 (rat)N/A
- LD50 (mouse)N/A